Standout Papers

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer p... 2010 2026 2015 2020 2.3k
  1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial (2010)
    Johann S. de Bono, Stéphane Oudard et al. The Lancet

Immediate Impact

3 by Nobel laureates 7 from Science/Nature 78 standout
Sub-graph 1 of 19

Citing Papers

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
2023 Standout
A neutrophil response linked to tumor control in immunotherapy
2023 Standout
3 intermediate papers

Works of Liji Shen being referenced

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
2014
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Liji Shen 2728 1240 1099 35 3.4k
Ivo Kocák 2416 1363 926 40 3.2k
William R. Berry 3834 1755 1244 22 4.8k
J Horti 3561 1592 1155 17 4.5k
Daniel H. Shevrin 2997 1164 1154 77 3.8k
Martin Roessner 2190 948 887 11 2.8k
Susan Feyerabend 3080 977 974 71 3.7k
Mary Ellen Taplin 4080 1528 950 27 5.0k
Matthew M. Cooney 3474 1773 1103 85 5.0k
Peter De Porre 2399 734 863 90 3.3k
Luis Fein 2530 1612 707 52 3.7k

All Works

Loading papers...

Rankless by CCL
2026